Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D59BZJ
|
|||
| Drug Name |
177Lu-labelled RM2
|
|||
| Drug Type |
Radiopharmaceutical therapy agent
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Investigative | [1] | |
| Company |
ABX GmbH
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastrin-releasing peptide receptor (GRPR) | Target Info | Antagonist | [1] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.